Cardiovascular benefits of sodium-glucose cotransporter 2 inhibitors in diabetic and nondiabetic patients

被引：12
|
作者：
Xiang, Boyang [1 ]
Zhao, Xiaoya [1 ]
Zhou, Xiang [1 ]
机构：
[1] Soochow Univ, Affiliated Hosp 2, Dept Cardiol, 1055 Sanxiang Rd, Suzhou 215004, Peoples R China
来源：
CARDIOVASCULAR DIABETOLOGY | 2021年 / 20卷 / 01期
关键词：
Sodium-glucose cotransporter 2 inhibitors; Cardiovascular benefits; Diabetes; GLYCATION END-PRODUCTS; PRESERVED EJECTION FRACTION; SERUM URIC-ACID; SELECTIVE SGLT2 INHIBITOR; EPICARDIAL ADIPOSE-TISSUE; HEART-FAILURE; ARTERIAL STIFFNESS; NA+/H+-EXCHANGER; BETA-HYDROXYBUTYRATE; GLYCEMIC CONTROL;
D O I：
10.1186/s12933-021-01266-x
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Sodium-glucose cotransporter 2 inhibitors (SGLT2i) were developed as antidiabetic agents, but accumulating evidence has shown their beneficial effects on the cardiovascular system. Analyses of the EMPA-REG OUTCOME trial (Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients) suggested that these benefits are independent of glycemic control. Several large-scale outcome trials of SGLT2i also showed cardiovascular benefits in nondiabetic patients, strengthening this perspective. Extensive animal and clinical studies have likewise shown that mechanisms other than the antihyperglycemic effect underlie the cardiovascular benefits. Recent clinical guidelines recommend the use of SGLT2i in patients with type 2 diabetes mellitus and cardiovascular diseases because of the proven cardiovascular protective effects. Since the cardiovascular benefits are independent of glycemic control, the therapeutic spectrum of SGLT2i will likely be extended to nondiabetic patients.
引用
收藏
页数：14
相关论文
共 50 条
  • [1] Cardiovascular benefits of sodium-glucose cotransporter 2 inhibitors in diabetic and nondiabetic patients
    Boyang Xiang
    Xiaoya Zhao
    Xiang Zhou
    [J]. Cardiovascular Diabetology, 20
  • [2] Benefits and Complications of Sodium-Glucose Cotransporter 2 Inhibitors
    Sangiovanni, Ryan J.
    DeVee, Carley E.
    [J]. US PHARMACIST, 2019, 44 (02) : HS9 - HS12
  • [3] Sodium-glucose cotransporter 2 inhibitors and diabetic ketoacidosis
    Bloomgarden, Zachary T.
    [J]. JOURNAL OF DIABETES, 2016, 8 (02) : 175 - 176
  • [4] Sodium-glucose cotransporter 2 inhibitors and cardiovascular outcomes
    Steinberg, Helmut O.
    [J]. POSTGRADUATE MEDICINE, 2016, 128 (04) : 398 - 408
  • [5] CARDIOVASCULAR BENEFITS OF SODIUM-GLUCOSE COTRANSPORTER 2 INHIBITORS AND ANGIOTENSIN-CONVERTING ENZYME INHIBITORS
    Patel, Amish
    Budoff, Matthew J.
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2019, 73 (09) : 1742 - 1742
  • [6] Balancing Risks and Benefits: Sodium-Glucose Cotransporter 2 Inhibitors and the Risk of Diabetic Ketoacidosis
    Kleinjan, Jan P.
    Blom, Justin
    van Beek, Andre P.
    Bouma, Hjalmar R.
    van Dijk, Peter R.
    [J]. METABOLITES, 2024, 14 (03)
  • [7] Evaluating the Benefits and Cost of the Sodium-Glucose Cotransporter 2 Inhibitors
    Nguyen, Quang T.
    [J]. AMERICAN HEALTH AND DRUG BENEFITS, 2015, 8 (06):
  • [8] Performance of sodium-glucose cotransporter 2 inhibitors in cardiovascular disease
    Khater, Jacinthe
    Malakouti, Sara
    El Khoury, Antoine
    Cortese, Bernardo
    [J]. JOURNAL OF CARDIOVASCULAR MEDICINE, 2024, 25 (04) : 247 - 258
  • [9] Treatment of Nondiabetic Kidney Diseases with Sodium-Glucose Cotransporter-2 Inhibitors
    Brosius, Frank C.
    [J]. CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2023, 18 (10): : 1359 - 1361
  • [10] Sodium-Glucose Cotransporter 2 Inhibitors
    Erol, Cetin
    [J]. ANATOLIAN JOURNAL OF CARDIOLOGY, 2024, 28 (05): : 216 - 216
12345